6 results
424B3
PRTG
Portage Biotech Inc
14 Nov 23
Prospectus supplement
6:00am
with PORT - 2 + pembrolizumab(n=2) experienced only low - grade AEs consistent with the safety profile of pembrolizumab Table 1: Demographics and Baseline
6-K
EX-99.1
PRTG
Portage Biotech Inc
13 Nov 23
Current report (foreign)
6:10am
) experienced only low - grade AEs consistent with the safety profile of pembrolizumab Table 1: Demographics and Baseline Characteristics (n=12) Melanoma: 6
6-K
EX-99.1
PRTG
Portage Biotech Inc
8 Sep 23
Current report (foreign)
4:01pm
%) Pruritus 0 0 1 (8%) AST/ALT elevation 0 0 1 (8%) Vomiting Table 1: Demographics and Baseline Characteristics (n=12) Melanoma: 6 (50) NSCLC 6 (50) Tumor
6-K
EX-99.1
PRTG
Portage Biotech Inc
14 Aug 23
Current report (foreign)
4:52pm
%) Pruritus 0 0 1 (8%) AST/ALT elevation 0 0 1 (8%) Vomiting Table 1: Demographics and Baseline Characteristics (n=12) Melanoma: 6 (50) NSCLC 6 (50) Tumor
6-K
EX-99.1
PRTG
Portage Biotech Inc
20 Jun 23
Current report (foreign)
5:53pm
: Demographics and Baseline Characteristics (n=12) Melanoma: 6 (50) NSCLC 6 (50) Tumor type (%) 64 (41,79) Age (range) 4 (2,7) Median prior therapies
6-K
EX-99.1
5rwcu40c9do
19 Feb 19
Report of Foreign Private Issuer
10:37am
- Prev
- 1
- Next